Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979557 | 0.75 | — | — | |
| Methyl Alcohol SCHEMBL27771562 | 0.72 | KMT2A (0.44) | KMT2ACA12CA1CA2CA9 | |
| Bromomethane SCHEMBL21803200 | 0.72 | CA12 (0.43) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL9005174 | 0.72 | CA12 (0.40) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL6131634 | 0.71 | — | — | |
| SCHEMBL4262422 | 0.71 | — | — | |
| SCHEMBL17635577 | 0.71 | — | — | |
| SCHEMBL6236180 | 0.71 | — | — | |
| SCHEMBL3955047 | 0.71 | — | — | |
| SCHEMBL196953 | 0.71 | CA12 (0.41) | KMT2ACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11400076-B2 | Cancer stem cell inhibitor | KEIO UNIVERSITY (JP) | 2022-08-02 | — | — | US | disclosed |
| US-20200316027-A1 | CANCER STEM CELL INHIBITOR | KEIO UNIVERSITY (JP) | 2020-10-08 | — | — | US | disclosed |
| EP-3692990-A1 | CANCER STEM CELL INHIBITOR | Keio University (JP) | 2020-08-12 | — | — | EP | disclosed |
| CN-111182897-A | Cancer stem cell inhibitors | 学校法人庆应义塾 | 2020-05-19 | — | — | CN | disclosed |
| EP-2116241-B1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-2156832-B1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC (JP) | 2014-06-25 | — | — | EP | disclosed |
| CN-101642452-B | Radiation sensitizer used for brain tumor | POLA PHARMA INC JP | 2014-05-28 | — | — | CN | disclosed |
| US-8541459-B2 | Pharmaceutical composition | POLA PHARMA INC. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8450356-B2 | Pharmaceutical composition | POLA PHARMA INC. (JP) | 2013-05-28 | — | — | US | disclosed |
| CN-101621997-B | Pharmaceutical composition | POLA PHARMA INC | 2013-05-08 | — | — | CN | disclosed |
| US-20120130148-A1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC. (JP) | 2012-05-24 | — | — | US | disclosed |
| CN-101541324-B | Pharmaceutical composition | POLA PHARMA INC | 2011-06-15 | — | — | CN | disclosed |
| US-20100130576-A1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100076042-A1 | PHARMACEUTICAL COMPOSITION | POLA PHARMA INC. (JP) | 2010-03-25 | — | — | US | disclosed |
| EP-2156832-A1 | PHARMACEUTICAL COMPOSITION | Pola Pharma Inc. (JP) | 2010-02-24 | — | — | EP | disclosed |
| CN-101642452-A | Radiation sensitizer used for brain tumor | POLA PHARMA INC JP | 2010-02-10 | — | — | CN | disclosed |
| CN-101621997-A | Pharmaceutical composition | POLA PHARMA INC | 2010-01-06 | — | — | CN | disclosed |
| EP-2116241-A1 | PHARMACEUTICAL COMPOSITION | Pola Pharma Inc. (JP) | 2009-11-11 | — | — | EP | disclosed |
| CN-101541324-A | Pharmaceutical composition | POLA PHARMA INC (JP) | 2009-09-23 | — | — | CN | disclosed |
| US-4462992-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION (US) | 1984-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076042-A1 | PHARMACEUTICAL COMPOSITION | MT-ND1, CYP2C19, KDM1A | KMT2A 700/4885CA12 3390/4885CA1 3169/4885 |
| US-20100130576-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, CYP2C18, CYP2D6 | KMT2A 3622/4885CA12 2996/4885CA1 4210/4885 |
| US-11400076-B2 | Cancer stem cell inhibitor | TFAM, COX4I1, MT-ND2 | KMT2A 557/4885CA12 3713/4885CA1 3541/4885 |
| US-20200316027-A1 | CANCER STEM CELL INHIBITOR | TFAM, COX4I1, MT-ND2 | KMT2A 557/4885CA12 3713/4885CA1 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.